Association of Cardiometabolic Disorders with Prostate Cancer Risk
Overview
Revise to clarify the impact of single CMD on non-aggressive PCa-specific mortality.
Background
Prostate cancer is a significant health concern, being the second most common malignancy among men globally. The rising prevalence of multimorbidity, particularly involving cardiometabolic disorders, necessitates an understanding of how these conditions interact with cancer risk. Evaluating the associations between CMDs and PCa can inform clinical management and risk assessment strategies.
Data Highlights
Condition
Hazard Ratio (HR)
95% Confidence Interval (CI)
Diabetes
1.18
1.08-1.29
Diabetes + Heart Disease
1.31
1.09-1.59
Single CMD (non-aggressive PCa mortality)
0.50
0.26-0.99
Key Findings
Baseline diabetes is associated with an 18% increased risk of developing prostate cancer.
Participants with diabetes and heart disease comorbidity have a 31% higher risk of prostate cancer incidence.
No significant association was found between CMDs and prostate cancer-specific mortality.
Having a single CMD significantly reduces the risk of non-aggressive prostate cancer-specific mortality.
Multimorbidity, particularly involving diabetes, influences prostate cancer risk and outcomes.
Clinical Implications
Healthcare professionals should consider the presence of diabetes and its comorbidities when assessing prostate cancer risk in patients. Understanding these associations can guide screening and management strategies for individuals with cardiometabolic disorders.
Conclusion
The findings underscore the importance of monitoring cardiometabolic health in relation to prostate cancer risk, particularly the role of diabetes and its interactions with other conditions. Further research is warranted to explore these relationships in diverse populations.
